Press Releases 

 

Perspective New Treatments in the Horizon for Traumatic Brain Injuries

Perspective New Treatments in the Horizon for Traumatic Brain Injuries

| October 3, 2016 | 0 comments
Milos Cekic; Donald G. Stein Future Neurology. 2010;5(1):3746. Abstract and Background Abstract Traumatic brain injury is a significant clinical problem for which there is still no effective treatment. Recent laboratory and clinical data demonstrate a potentially beneficial role for neurosteroids, such as progesterone and allopregnanolone, in the treatment of traumatic brain injury, ischemic stroke and some neurodegenerative
iPharmaTrials, News, Press Releases
Allergen Purchases Tobira Therapeutics

Allergen Purchases Tobira Therapeutics

| September 21, 2016 | 0 comments
Allergan Plc’s agreement to buy Tobira Therapeutics Inc. for as much as $1.7 billion sent biotech stocks soaring Tuesday, as investors bet that buyers will emerge for other companies developing experimental treatments for a liver disease known as NASH. NASH, or non-alcoholic steatohepatitis, is a severe type of fatty liver disease that has become one of the hottest areas in biotech
Allergen, Conatus Pharmaceuticals, Galectin Therapeutics, Gilead, Intercept Pharmaceuticals, Tobira Therapeutics
iPharmaTrials, News, Press Releases
MRI Scans May Be Useful in Diagnosing Chronic Traumatic Encephalopathy

MRI Scans May Be Useful in Diagnosing Chronic Traumatic Encephalopathy

| September 18, 2016 | 0 comments
Originally posted on neurosciencenews.com Summary: Researchers report MRI brain scans may be an early and easier way to diagnose CTE. Source: UCLA. UCLA doctors have found what may be an earlier and easier way to diagnose chronic traumatic encephalopathy, or CTE, a disorder that is thought to affect some former football players and others with
CTE, MRI, PET
iPharmaTrials, News, Press Releases
AbbVie to Expand Oncology Presence

AbbVie to Expand Oncology Presence

| June 8, 2016 | 0 comments
AbbVie: To Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer NORTH CHICAGO, Ill., April 28, 2016 /PRNewswire/ — AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell
AbbVie, Oncology, Pharmacyclics, Rova-T, Stemcentrx
iPharmaTrials, News, Press Releases
Genes Link Stroke & Dementia

Genes Link Stroke & Dementia

| April 27, 2016 | 0 comments
Researchers have identified a new set of genes that may be responsible for the two most common and disabling neurological conditions, stroke and dementia. Published online April 7 2016 doi:10.1016/S1474-4422(16)00102-2 The study, which appears in the journal Lancet Neurology, may help researchers better understand, treat and prevent ischemic and hemorrhagic stroke, and perhaps Alzheimer’s disease
Dementia, genes, Stroke
iPharmaTrials, News, Press Releases
Pneumonoultramicroscopicsilicovolcanoconiosis

Pneumonoultramicroscopicsilicovolcanoconiosis

| March 24, 2016 | 0 comments
Pneumonoultramicroscopicsilicovolcanoconiosis is the longest word in the English language published in the Oxford English Dictionary. This word refers to silicosis which is a lung disease caused by breathing in tiny dust particles of crystalline silica which is a combination of silicon and oxygen. This mineral is widely found in the Earth’s crust. Silicosis is the most
iPharmaTrials, IPT Documents, News, Press Releases
Epidiolex

Epidiolex

| March 24, 2016 | 0 comments
Epidiolex is a liquid formulation of pure plant-derived Cannabidiol (CBD), as a treatment for various orphan pediatric epilepsy syndromes, for which FDA has granted Orphan Drug Designation in the treatment of Dravet syndrome and Lennox-Gastaut syndrome and Fast Track Designation for Dravet syndrome. According to Russ in the February 2012 edition of Pediatrics, there is
iPharmaTrials, IPT Documents, News, Press Releases

Neuroimaging Techniques

| March 7, 2016 | 0 comments
Mild Traumatic Brian Injury Advancement’s in TBI and biochemical research may be predicting neuropsychiatric outcome in mild TBI subject’s adjunct to neuroimaging techniques.
biochemical research, Mild Traumatic Brian Injury, neuroimaging techniques, neuropsychiatric, TBI
iPharmaTrials, News, Press Releases
MEDICAL MARIJUANA AVAILABLE IN NY

MEDICAL MARIJUANA AVAILABLE IN NY

| January 28, 2016 | 0 comments
NEWS FLASH! MEDICAL MARIJUANA AVAILABLE IN NY On July 5, 2014, NYS Governor Andrew Cuomo signed a limited medical marijuana bill into law. Medical marijuana may not be smoked nor consumed in a public place. This became a reality in January 2016. Medical Marijuana is only available from a dispensary. Your physician must register with
iPharmaTrials, News, Press Releases
CONCUSSION UPDATE

CONCUSSION UPDATE

| December 28, 2015 | 0 comments
A concussion or mild traumatic brain injury (MTBI) is most often caused by a sudden direct blow or bump to the head which causes a temporary loss of neural activity. The following are common concussion symptoms: Absence of consciousness or altered consciousness, headache, confusion, disorientation, vision disturbances, dizziness, nausea or vomiting, impaired balance, memory loss, tinnitus or ringing in
concussion, diffuse tensor imaging, mild traumatic brain injury
iPharmaTrials, News, Press Releases

Resources

 

– Krishna’s Corner
– Krishna’s Blog
– Store

iPT Tweets

 

News

 

iPHARMA TRIALS

 

New York, USA
Telephone : 718-332-7878
rkrishna -AT- ipharmatrials.com
.. replace -AT- with @

United Kingdom
The Studio/East Batterlaw Farm
Seaham SR7 8RP

Corporation Registration Address:
330 Thornton Road Englewood NJ 07631